Logo for Cipher Pharmaceuticals Inc

Cipher Pharmaceuticals Investor Relations Material

Latest events

Logo for Cipher Pharmaceuticals Inc

Q3 2023

Cipher Pharmaceuticals
Logo for Cipher Pharmaceuticals

Q3 2023

10 Nov, 2023
Logo for Cipher Pharmaceuticals

Q2 2023

11 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Cipher Pharmaceuticals Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, and commercializing prescription products for the dermatology market in Canada. The company's commercial products include Epuris, a recombinant formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin for treating impetigo; Actikerall, which is indicated for the treatment of hyperkeratotic actinic keratosis; Vaniqa that reduces the growth of unwanted facial hair in women; BRINAVESS, an antiarrhythmic agent for the conversion of recent onset or well-tolerated atrial fibrillation; and AGGRASTAT, an intravenous anti-platelet drug. It also develops PEP005 (ingenol mebutate) gel that completed Phase III clinical trials for actinic keratosis and keloid scars; and CIP-Liprodex (DFF 450), which is in Phase II clinical trials to treat localized liposarcomas.